Fig. 4
From: CAR-T cell therapy for cancer: current challenges and future directions
Main characteristics of the most common antigens targeted with current directed therapies for AML and relevant clinical trials. Antibody-drug conjugates (ADC) targeting CD123 shown are Tagraxofusp in monotherapy (208); Tagraxofusp + Azacitidine ± Venetoclax (209); IMGN63 (210); IMGN63 +Venetoclax + Azacitidine (211). Biespecific T-cell Engagers (BiTE) targeting CD123 exposed are Vibecotamab (212); Flotetuzumab (213); JNJ-63709178 (214); and MGD024 (215). Monoclonal Antibodies (mAb) targeting CD38 are isatuximab in combination with chemotherapy (268). BiTE targeting CD33 are AMG330 (233) and AMG673 (235). AZA Azacitidine, Ven Venetoclax, CT chemotherapy, CR complete response, CRi complete response with incomplete hematologic recovery, PR partial response, ND new diagnosed, R/R refractory/relapsed, ORR Overall Response Rate, SD stable disease, This figure was created with Biorender.com
